What is Unicycive Therapeutics Inc (UNCY) stock price today?

Unicycive Therapeutics Inc (UNCY) currently trades at $7.66 per share. The stock has a market capitalization of $180.96M and a P/E ratio of —x.

Is UNCY stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Unicycive Therapeutics Inc has a Smart Value Score of 19/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -6.79.

Is Unicycive Therapeutics Inc financially healthy?

Unicycive Therapeutics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -6.79 places it in the distress.

UNCY

Unicycive Therapeutics Inc

NASDAQ: UNCY · HEALTHCARE · BIOTECHNOLOGY

$7.66

+6.98% today

Updated 2026-04-30

Market cap

$180.96M

P/E ratio

—

P/S ratio

23.75x

EPS (TTM)

$-1.67

Dividend yield

—

52W range

$4 – $11

Volume

0.5M

Market cap

$180.96M

P/E ratio

—

P/S ratio

23.75x

EPS (TTM)

$-1.67

Dividend yield

—

52W range

$4 – $11

Volume

0.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-6.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$43.46

+467.36%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -6.79 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-8.03M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$951000.00	$675000.00	$0.00	$0.00	$0.00
Net income	$-18.06M	$-30.54M	$-36.73M	$-26.55M	$-14.67M
EPS	—	—	—	—	$-1.67
Free cash flow	$-15.65M	$-18.30M	$-28.65M	$-31.34M	$-8.03M
Profit margin	-1,899.47%	-4,525.04%	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
UNCY	$180.96M	19	4.3	3.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Unicycive Therapeutics Inc trades at $7.66. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -6.79, it sits in the distress.

Frequently asked questions

What is Unicycive Therapeutics Inc's stock price?

Unicycive Therapeutics Inc (UNCY) trades at $7.66.

Is Unicycive Therapeutics Inc overvalued?

Smart Value Score 19/100 (Grade F, Strong Sell).

What is the price target of Unicycive Therapeutics Inc (UNCY)?

The analyst target price is $43.46, representing +467.4% upside from the current price of $7.66.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-6.79 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

unicycive.com

Quick metrics

P/S ratio23.75x

ROE-141.10%

Beta1.80

50D MA$6.82

200D MA$5.57

Shares out0.03B

Float0.02B

Short ratio—

Avg volume0.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

UNCY vs LLY →UNCY vs JNJ →UNCY vs ABBV →Stock screener →